Shared Gene Therapy Panel Could Cover 76% of Cases

Modeling suggests four antisense oligonucleotides could reach most people with SCN2A disorders, though the extra candidates still need lab testing.

Updated on Nov. 5, 2026 in Biotech

Shared Gene Therapy Panel Could Cover 76% of Cases

Researchers led by Stephen Kingsmore of Cleveland Clinic designed antisense oligonucleotides (ASOs) targeting common genetic variations linked to SCN2A-related disorders, with results published in The American Journal of Human Genetics. The work is research-stage: two ASOs were originally developed for individual children and showed sustained improvement over two years, while the additional candidates remain computational and require laboratory validation.

Why it matters

Individual ASOs designed for one patient's mutation may have little therapeutic value for others, which has limited the reach of bespoke genetic therapies. The study's modeling suggests a shared panel of ASOs could address a much larger share of patients, pointing toward reusable rather than one-off treatments.

The 48% figure reflects a retrospective analysis of 21 patients, while the 76.2% coverage figure is a modeled estimate drawn from 2,504 reference genomes rather than measured patient outcomes. Only the two original ASOs have clinical data, and those rest on individualized trials in single children.

The players

Cleveland Clinic

A large U.S. academic medical center whose researchers led the study of genetic therapies for SCN2A-related disorders.

Stephen Kingsmore

Lead researcher on the study, based at Cleveland Clinic, with a track record in genomic medicine and rapid genome sequencing.

The details

Antisense oligonucleotides are short synthetic strands of genetic material that bind to RNA to suppress the production of a particular protein. The approach here targets shared haplotype sequences, which are stretches of DNA inherited together across people, to selectively suppress expression from the chromosome carrying a harmful mutation. Whole-genome sequencing distinguishes the two inherited copies of a gene, which is what allows researchers to pick the copy to silence.

Timeline

  1. Two years of sustained clinical improvement were recorded in the original individualized trial children.

  2. The article was published on November 5, 2026.

The Tech Race

The work moves individualized ASO therapy toward a platform model, a direction that separates it from one-patient approaches. Its direct competitors are other programs designing genetic medicines for rare neurological disorders, though the evidence here remains at the modeling and early clinical stage.

Patients with SCN2A-related disorders would not see these candidate ASOs in use until laboratory validation and clinical trials are completed, and no timeline has been announced. The near-term effect is on research direction, not on available treatment.

The takeaway

If the modeled coverage holds up, a shared ASO panel would move genetic therapy for SCN2A disorders from bespoke design toward reusable medicine. Watch for laboratory validation of the two-to-four additional candidates, which would be the first test of whether the 76.2% estimate reflects biology.

Further reading

For background on the genetic medicines this research builds on, see the Biotech section.

Source note: This article includes information reported by Inside Precision Medicine.